#SomaScan
Authors then used the somascan for the serum of patients. Somascan can detect 5000 proteins in parallel. Authors detected 287 proteins where expression changed, and 99 that changed a lot. These were involved in immune response, extracellular matrix formation and iron transport.
October 31, 2026 at 7:43 AM
The first four patients who were treated by Elevidys (before it was called Elevidys) had only mild and moderate side effects. However, authors argue that likely one can still see signs of an immune response in their blood. To study this in detail authors used the somascan system.
October 31, 2026 at 7:40 AM
Край на болезнената биопсия: Учени откриха кои два кръвни теста най-добре показват здравето на черния дроб

Две мащабни международни проучвания показаха кои диагностични методи най-добре се справят с оценката на фиброзата и цирозата на черния дроб без биопсия. Оказа се, че обикновеният кръвен тест…
Край на болезнената биопсия: Учени откриха кои два кръвни теста най-добре показват здравето на черния дроб
Две мащабни международни проучвания показаха кои диагностични методи най-добре се справят с оценката на фиброзата и цирозата на черния дроб без биопсия. Оказа се, че обикновеният кръвен тест за гама-глутамилтрансфераза (ГГТ) и протеомният панел SOMAScan (кръвни тестове за показатели на протеините) позволяват с висока точност да се установят не само уврежданията на черния дроб, но и рисковете от прогресиране на заболяванията, без да се взема проба от тъканта. Учените оцениха десетки диагностични методи, включително кръвни изследвания, ултразвук и ЯМР. В двете проучвания участваха близо 2 хил. човека. За резултатите пише
www.kaldata.com
October 30, 2026 at 1:00 PM
Working with KPMP biomarker data? Atlas v23 adds aggregated long-format files for Central Lab, Litholink, Meso Scale Discovery, Metabolon, and SomaScan, ready to drop straight into your analysis pipelines. 📊

atlas.kpmp.org

#KidneyWk #OpenData
Kidney Tissue Atlas
The Kidney Tissue Atlas is a set of interactive tools built to promote retrieval, exploration, discovery, and analysis of the KPMP data by the greater research community.
atlas.kpmp.org
October 23, 2026 at 2:58 PM
(JPR) Targeted Analysis
of >1500 Plasma Proteoforms via
Individual Ion Mass Spectrometry: AbstractPlasma proteomics has emerged as a powerful approach
for interrogating
human biology, identifying disease-associated proteomic changes, and
advancing precision diagnostics. In recent… #MassSpecRSS
Targeted Analysis of >1500 Plasma Proteoforms via Individual Ion Mass Spectrometry
AbstractPlasma proteomics has emerged as a powerful approach for interrogating human biology, identifying disease-associated proteomic changes, and advancing precision diagnostics. In recent years, affinity-based plasma proteomics platforms with predefined protein panels, such as Olink and SomaScan, have emerged to complement bottom-up mass spectrometry (BUP). This study leverages a novel mass spectrometry platform to capture targeted proteoform information lost by mainline antibody-, aptamer-, and BUP-driven workflows. The Plasma Proteoform Assay (PPA) uses Individual Ion Mass Spectrometry (I2MS) to resolve mixtures of intact proteins presented by direct injection. Two proteoform panels, PPA 526 and PPA 1514, were defined from human plasma samples obtained from 81 individuals. The panels quantify 526 proteoforms derived from 59 genes and 1,514 proteoforms from 155 genes, respectively. Across both panels, the proportion of targeted proteoforms with CVs below 20% ranged from 59% to 80%. PPA was benchmarked in studies including 9 pooled plasma samples derived from subjects with hepatic cirrhosis (N = 30 individuals) and a cohort of resilient agers carrying a SERPINE1 (PAI-1) mutation (N = 27 individuals). PPA signatures distinguished SERPINE1 mutation carriers from affected individuals and provided sufficient resolution to discriminate among cirrhosis disease stages. In summary, we present PPA 526 and PPA 1514, the first scalable plasma proteoform panels capable of tracking hundreds to thousands of targets in a few minutes per sample.
dlvr.it
October 9, 2026 at 2:58 PM
Plasma samples (n = 504) analysed using SomaScan, finds lysosomal expression scores discriminate #Parkinsons from controls & associated with disease severity. SUMF1 & ARRDC3 emerged as blood-based biomarkers for PD
movementdisorders.onlinelibrary.wiley.com/doi/10.1002/...
September 23, 2026 at 2:56 AM
(BioRxiv All) ProtPipe2: Multi-Platform Downstream Proteomics Analysis Tool: Proteomics studies increasingly use different technologies, including mass spectrometry, the antibody-based Olink platform, and the aptamer-based SomaScan platform. However, downstream analysis often… #BioRxiv #MassSpecRSS
ProtPipe2: Multi-Platform Downstream Proteomics Analysis Tool
Proteomics studies increasingly use different technologies, including mass spectrometry, the antibody-based Olink platform, and the aptamer-based SomaScan platform. However, downstream analysis often depends on platform-specific scripts or point-and-click tools, limits flexibility and makes analyses difficult to reuse across platforms. We developed ProtPipe2, a downstream proteomics analysis framework for mass spectrometry, Olink, and SomaScan data that is available as both an R package and an interactive web application. ProtPipe2 supports quality control, preprocessing, imputation, batch correction, statistical analysis, visualization, pathway analysis, and result export. ProtPipe2 expands the original Protpipe workflow to additional proteomics platforms and provides reusable R functions for imputation, batch correction, and other downstream analyses. Its redesigned web application provides user-controlled methods and parameters through the same R-based workflow. Case studies across mass spectrometry, Olink, and SomaScan datasets demonstrated a consistent downstream analysis workflow across platforms. By supporting three proteomics platforms through both graphical and scripted workflows, ProtPipe2 makes downstream analysis easier to perform, repeat, and review. ProtPipe2 is freely available at https://nih-card.github.io/ProtPipe2/.
dlvr.it
September 22, 2026 at 6:58 AM
test this technology in other diagnoses where we believe neuroinflammation to be driving cognitive symptoms: #concussion, #TBI, #stroke, #mecfs and chronic #lyme. These are incredibly promising results and I'm so grateful to the brilliant team at SomaScan as well as the
9/
August 31, 2026 at 4:48 PM
Somascan uses synthetic DNA probes as molecular detectors, this method can precisely measure over 10,000 proteins simultaneously in blood plasma. This technique is very sensitive to changes in protein expression between timepoints that may be driving improvements in symptoms.
4/
August 31, 2026 at 4:48 PM
control arm. What was cool about this study was that we also captured plasma at different stages of the trial and in collaboration with Somascan #proteomics, we took a look at differences in proteomic readout in the MMT trial participants (preprint👇)

www.medrxiv.org/content/10.6...

3/
Plasma Proteomics Identifies a Microtesla Magnetic Therapy Response Signature in Long COVID
Cognitive impairment is a disabling feature of Long COVID with no established disease-modifying therapy, and little is known about the biological changes accompanying clinical improvement. Microtesla ...
www.medrxiv.org
August 31, 2026 at 4:48 PM
Circulating Proteomic
Signatures for Multicancer Early
Detection: Cross-Platform Evidence for a Matrix–Immune–Secretory
Biomarker Axis: AbstractBlood-based
proteomics may complement existing MCED approaches
by capturing tumor-secreted proteins and systemic host responses.
We reviewed prospective…
Circulating Proteomic Signatures for Multicancer Early Detection: Cross-Platform Evidence for a Matrix–Immune–Secretory Biomarker Axis
AbstractBlood-based proteomics may complement existing MCED approaches by capturing tumor-secreted proteins and systemic host responses. We reviewed prospective and multicancer studies published from 2020 to 2025 that used Olink, SomaScan, or mass spectrometry and compared evidence from case–control and prospective designs. Candidate proteins were classified as established or novel and evaluated using pathway and cancer-hallmark enrichment analyses, GEPIA3.0 Cox analyses, TCGA Kaplan–Meier survival curves, and TPCPA/RPPA protein abundance data. Across platforms, established markers, including CEACAM5, WFDC2/HE4, and GDF15 were complemented by novel candidates converging on a matrix–immune–secretory axis. This axis included MMP12 and ADAM8, CD74 and CXCL13, TGFB1, and CDCP1. Secretory and matrix-associated candidates were linked to poorer survival in several epithelial cancers, whereas immune-associated proteins showed context-dependent effects. Tumor-type-specific protein elevation supported their detectability, and interaction analysis organized the candidates into biologically coherent modules. These findings support an MCED framework combining higher-risk secretory and matrix markers with immune-context indicators to improve sensitivity and biological interpretation. Prospective validation and down-selection into scalable targeted assays are required before population-level application.
dlvr.it
August 31, 2026 at 11:01 PM
PTSD linked to 114 proteins and 7 metabolites in 393 tested, hinting at redox-metabolic pathway roles in disease risk and aging. Major factors: NCAN, BCAN, NCAM1, GDF15. PMID:42323343, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-74757-8 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Integrated proteomic and metabolomic analyses implicate redox-metabolic pathways in PTSD-associated multisystem disease and accelerated aging | Nature Communications
Posttraumatic stress disorder (PTSD) is associated with increased risk of chronic disease and premature aging, yet underlying molecular mechanisms remain unclear. We performed plasma proteomics (SomaScan; 9404 proteins) and targeted metabolomics (145 metabolites) in 393 World Trade Center responders (232 with PTSD, 161 trauma-exposed controls). A total of 114 proteins and seven metabolites were differentially expressed in PTSD. Top proteins included NCAN, BCAN, NCAM1, and GDF15. Top metabolites included serotonin, lactate, glutamic acid, and cystathionine. Integrative analyses showed coordinated proteomic-metabolomic alterations, with widespread correlations linking metabolites involved in redox and amino acid metabolism to synaptic and oxidative stress-related proteins. Gene ontology enrichment identified neuronal plasticity, immune activation, extracellular matrix remodeling, and oxidative stress. Proteomic organ aging analyses revealed accelerated aging in the pancreas, lung, and at
doi.org
August 30, 2026 at 10:00 AM
bei ME/CFS-Patienten ermöglichen, und die Hypothese eines mit dem Immunsystem zusammenhängenden Grundmechanismus zu untersuchen, der zu einer Beeinträchtigung der Mikrozirkulation und des Energiestoffwechsels führt.
„Wir haben bei 54 ME/CFS-Patienten und 27 gesunden
June 1, 2025 at 9:07 PM
interesting choice (SomaScan)!
July 21, 2025 at 2:00 PM
My view is that there are regulatory explanations for the missing correlation between RNA and protein. That shouldn't be the case for the proteomics made by Olink and SomaScan.
February 23, 2025 at 4:04 PM
SomaScan Surveying the Breadth and Depth of the Human Proteome

View eBook By creating the first complete map of the human genome, the Human Genome Project made genetics an everyday topic that any well-informed person could comment on. Even so, the human genome is only part of the blueprint of…
SomaScan Surveying the Breadth and Depth of the Human Proteome
View eBook By creating the first complete map of the human genome, the Human Genome Project made genetics an everyday topic that any well-informed person could comment on. Even so, the human genome is only part of the blueprint of human biology. The real brick-and-mortar building blocks of the body are the constantly changing proteins that make up every structure and are involved in every function.
nexttech-news.com
December 24, 2025 at 11:31 PM
Standard BioTools sells SomaScan proteomics unit to Illumina for up to $425M, exits diagnostics

$LAB 10-K → https://filingdiff.com/ticker/LAB/0001193125-26-108326/
June 5, 2026 at 12:10 AM
Version 25 of the Human Protein Atlas is launched. New additions are Olink Explore HT and SomaScan data for 32 cohorts including diseases and childhood development, more single cell data with 4 new tissues and 23000 predicted structures for protein interactions

www.proteinatlas.org/news/2025-11...
November 11, 2025 at 1:37 PM
Even a hard spin for platelet poor plasma would still contain EVs I would think. Whether olink and somascan would equally detect proteins in EVs though, that I don't know
November 24, 2024 at 4:16 AM
A somascan analysis was done, which allows evaluation of many proteins. This confirmed the mineralcorticoid antagonistic profile of vamorolone. This was seen when comparing baseline samples with after vamorolone initiation samples, and also when patients switched from prednisone to vamorolone.
October 17, 2025 at 7:05 AM
Here authors performed serum profiling of patients using samples taken at baseline & after 24 weeks using the aptamer SomaScan analysis tool that can do targeted measurement of 6411 proteins. Note that the patients were heterogeneous with variants in dystrophin, calpain 3, dysferlin, titin and FKRP
December 4, 2024 at 8:49 AM
Predictors of response to terlipressin therapy in hepatorenal syndrome: Metabolomic and proteomic analysis from the CONFIRM trial #HepatolCommun #MassSpec journals.lww.com/hepcomm/full...
Predictors of response to terlipressin therapy in... : Hepatology Communications
atment initiation were tested using (a) liquid chromatography–mass spectrometry of 1594 plasma/1420 urine metabolites (Metabolon Inc.), (b) aptamer-based array of 7289 plasma proteins (SomaScan), and ...
journals.lww.com
July 15, 2025 at 12:53 PM
This paper utilizes SOMAscan data to address critical issues in biomarker discovery, particularly the effects of sample size: bmcgenomics.biomedcentral.com/articles/10....
Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study - BMC Genomics
Background One of the most promising approaches for early and more precise disease prediction and diagnosis is through the inclusion of proteomics data augmented with clinical data. Clinical proteomic...
bmcgenomics.biomedcentral.com
February 21, 2025 at 7:25 PM
We will need a serious sarcasms filter to discuss that😁. And a real head-to-head comparison to MS to finally know how bad it really is. Btw O-Link is our company's go to over SomaScan, I will try to dig deeper on why we decided like that.
November 9, 2023 at 1:48 AM